{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T00:05:34Z","timestamp":1794787534845,"version":"4.9.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"DOI":"10.1186\/s13643-025-02923-y","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T07:20:00Z","timestamp":1756106400000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Hepatitis B reactivation with TNF-\u03b1 inhibitors: assessing antiviral prophylaxis efficacy \u2014 protocol for systematic review and meta-analysis"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5027-2096","authenticated-orcid":false,"given":"Alhalabi","family":"Marouf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sawan","family":"Sedra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"key":"2923_CR1","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/s00296-022-05136-x","volume":"42","author":"G Evangelatos","year":"2022","unstructured":"Evangelatos G, Bamias G, Kitas GD, Kollias G, Sfikakis PP. The second decade of anti-TNF-a therapy in clinical practice: new lessons and future directions in the COVID-19 era. Rheumatol Int. 2022;42:1493\u2013511.","journal-title":"Rheumatol Int"},{"key":"2923_CR2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.clim.2018.03.013","volume":"191","author":"WT Clarke","year":"2018","unstructured":"Clarke WT, Amin SS, Papamichael K, Feuerstein JD, Cheifetz AS. Patients with core antibody positive and surface antigen negative hepatitis B (anti-HBc+, HBsAg\u2212) on anti-TNF therapy have a low rate of reactivation. Clin Immunol. 2018;191:59\u201362.","journal-title":"Clin Immunol"},{"key":"2923_CR3","doi-asserted-by":"publisher","first-page":"522","DOI":"10.5152\/tjg.2020.19295","volume":"31","author":"S Sayar","year":"2020","unstructured":"Sayar S, K\u00fcrb\u00fcz K, Kahraman R, \u00d6zt\u00fcrk O, \u00c7al\u0131\u015fkan Z, Do\u011fanay HL, et al. Risk of hepatitis B reactivation during anti-TNF therapy; evaluation of patients with past hepatitis B infection. Turk J Gastroenterol. 2020;31:522\u20138.","journal-title":"Turk J Gastroenterol"},{"key":"2923_CR4","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/1756-185X.14034","volume":"24","author":"S Fidan","year":"2021","unstructured":"Fidan S, Capk\u0131n E, Ar\u0131ca DA, Durak S, Okatan IE. Risk of hepatitis B reactivation in patients receiving anti-tumor necrosis factor-\u03b1 therapy. Int J Rheum Dis. 2021;24:254\u20139.","journal-title":"Int J Rheum Dis"},{"key":"2923_CR5","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1111\/apt.17155","volume":"56","author":"H El Jamaly","year":"2022","unstructured":"El Jamaly H, Eslick GD, Weltman M. Meta-analysis: hepatitis B reactivation in patients receiving biological therapy. Aliment Pharmacol Ther. 2022;56:1104\u201318.","journal-title":"Aliment Pharmacol Ther"},{"key":"2923_CR6","doi-asserted-by":"publisher","unstructured":"Abel AM, Yang C, Thakar MS, Malarkannan S. Natural killer cells: development, maturation, and clinical utilization. Front Immunol. [cited 2024 May 18]2018;9. Available from: https:\/\/www.frontiersin.org\/journals\/immunology\/articles\/https:\/\/doi.org\/10.3389\/fimmu.2018.01869\/full","DOI":"10.3389\/fimmu.2018.01869\/full"},{"key":"2923_CR7","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/j.jhep.2022.07.003","volume":"77","author":"GV Papatheodoridis","year":"2022","unstructured":"Papatheodoridis GV, Lekakis V, Voulgaris T, Lampertico P, Berg T, Chan HLY, et al. Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: a systematic review, meta-analysis, and expert opinion. J Hepatol. 2022;77:1670\u201389.","journal-title":"J Hepatol"},{"key":"2923_CR8","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1097\/MD.0b013e3182380a76","volume":"90","author":"R P\u00e9rez-Alvarez","year":"2011","unstructured":"P\u00e9rez-Alvarez R, D\u00edaz-Lagares C, Garc\u00eda-Hern\u00e1ndez F, Lopez-Roses L, Brito-Zer\u00f3n P, P\u00e9rez-de-Lis M, et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore). 2011;90:359.","journal-title":"Medicine (Baltimore)"},{"key":"2923_CR9","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s12072-021-10239-x","volume":"15","author":"G Lau","year":"2021","unstructured":"Lau G, Yu M-L, Wong G, Thompson A, Ghazinian H, Hou J-L, et al. APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy. Hepatol Int. 2021;15:1031\u201348.","journal-title":"Hepatol Int"},{"key":"2923_CR10","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver, European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370\u201398.","journal-title":"J Hepatol"},{"key":"2923_CR11","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1093\/ecco-jcc\/jjab052","volume":"15","author":"T Kucharzik","year":"2021","unstructured":"Kucharzik T, Organisation [ECCO on behalf of the EC and C, Ellul P, Organisation [ECCO on behalf of the EC and C, Greuter T, Organisation [ECCO on behalf of the EC and C, et al. ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease. J Crohns Colitis. 2021;15:879\u2013913.","journal-title":"J Crohns Colitis"},{"key":"2923_CR12","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1097\/MEG.0b013e3283329d13","volume":"22","author":"X Verhelst","year":"2010","unstructured":"Verhelst X, Orlent H, Colle I, Geerts A, De Vos M, Van Vlierberghe H. Subfulminant hepatitis B during treatment with adalimumab in a patient with rheumatoid arthritis and chronic hepatitis B. Eur J Gastroenterol Hepatol. 2010;22:494\u20139.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2923_CR13","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1136\/gut.2004.040675","volume":"53","author":"M Esteve","year":"2004","unstructured":"Esteve M, Saro C, Gonz\u00e1lez-Huix F, Suarez F, Forn\u00e9 M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn\u2019s disease patients: need for primary prophylaxis. Gut. 2004;53:1363\u20135.","journal-title":"Gut"},{"key":"2923_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MEG.0000000000002863","volume":"37","author":"MM Alhalabi","year":"2025","unstructured":"Alhalabi MM, Almokdad R. The incidence of hepatitis B reactivation in patients receiving ustekinumab: a systematic review and proportional meta-analysis. Eur J Gastroenterol Hepatol. 2025;37:1\u20139.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2923_CR15","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/apt.17682","volume":"58","author":"M-H Kuo","year":"2023","unstructured":"Kuo M-H, Tseng C-W, Shao S-C. Letter: incidence of hepatitis B virus reactivation in patients with psoriasis treated with cytokine inhibitors. Aliment Pharmacol Ther. 2023;58:850\u20131.","journal-title":"Aliment Pharmacol Ther"},{"key":"2923_CR16","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","volume":"10","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10:89.","journal-title":"Syst Rev"},{"key":"2923_CR17","doi-asserted-by":"publisher","first-page":"n160","DOI":"10.1136\/bmj.n160","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372: n160.","journal-title":"BMJ"},{"key":"2923_CR18","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1001\/jamasurg.2021.0522","volume":"156","author":"BS Brooke","year":"2021","unstructured":"Brooke BS, Schwartz TA, Pawlik TM. MOOSE reporting guidelines for meta-analyses of observational studies. JAMA Surg. 2021;156:787\u20138.","journal-title":"JAMA Surg"},{"key":"2923_CR19","unstructured":"Sk S, M K, Gk L, Z A, Hl C, Cj C, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatology international. [cited 2023 Apr 7]2016;10. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26563120\/"},{"key":"2923_CR20","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, Chang K-M, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560.","journal-title":"Hepatology"},{"key":"2923_CR21","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355: i4919.","journal-title":"BMJ"},{"key":"2923_CR22","unstructured":"West SL, Gartlehner G, Mansfield AJ, Poole C, Tant E, Lenfestey N, et al. Table 7, Summary of common statistical approaches to test for heterogeneity. Agency for Healthcare Research and Quality (US); [cited 2024 Apr 11] 2010. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK53317\/table\/ch3.t2\/"},{"key":"2923_CR23","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u201334.","journal-title":"BMJ"},{"key":"2923_CR24","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 [Internet]. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al., editors. Cochrane Collaboration: Cochrane; 2021. Available from: https:\/\/training.cochrane.org\/handbook\/current."},{"key":"2923_CR25","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177\u201388.","journal-title":"Control Clin Trials"},{"key":"2923_CR26","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1053\/j.gastro.2014.10.039","volume":"148","author":"KR Reddy","year":"2015","unstructured":"Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT. American gastroenterological association institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148:215\u20139.","journal-title":"Gastroenterology"},{"key":"2923_CR27","doi-asserted-by":"crossref","unstructured":"Cohen EB, Regev A, Garg A, Di Bisceglie AM, Lewis JH, Vierling JM, et al. Consensus guidelines: best practices for the prevention, detection and management of hepatitis B virus reactivation in clinical trials with immunosuppressive\/immunomodulatory therapy. Drug Saf. 2024;1\u201312.","DOI":"10.1007\/s40264-024-01399-4"},{"key":"2923_CR28","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s00266-022-02977-6","volume":"47","author":"Y Chen","year":"2023","unstructured":"Chen Y, Chen D, Wang Y, Han Y. Using freeman-tukey double arcsine transformation in meta-analysis of single proportions. Aesth Plast Surg. 2023;47:83\u20134.","journal-title":"Aesth Plast Surg"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-025-02923-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13643-025-02923-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-025-02923-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T22:09:51Z","timestamp":1757455791000},"score":1,"resource":{"primary":{"URL":"https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/s13643-025-02923-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2923"],"URL":"https:\/\/doi.org\/10.1186\/s13643-025-02923-y","relation":{},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,25]]},"assertion":[{"value":"28 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study does not require ethical review or clearance as it involves conducting a meta-analysis  based solely on data from previously published studies. No patients or members of the public were  involved in the design or planning of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. We have not included any individual\u2019s data in our study protocol.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests. To enhance openness while minimizing  possible biases, the research team has taken several measures: all members have disclosed their  affiliations, funding sources, and potential competing interests prior to the review, any study  authored by a team member will be evaluated by independent reviewers within the team to avoid  bias, this review is not funded by any external organization or entity with a vested interest in its  outcomes, and the protocol adheres to PRISMA (Preferred Reporting Items for Systematic reviews  and Meta-Analysis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"169"}}